Q-omics provides the consensus-scored CCN1 profile across patient tissues and cancer cell-line models. CCN1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, CCN1 is differentially expressed in 10, with the highest sampling consensus in BLCA. Additionally, CCN1 RNA expression shows 19,600 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUSC, BLCA, and LSCC as cancer lineages where CCN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCN1 survival associations across molecular data types. CCN1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCN1 RNA expression–survival associations across cancer types. High CCN1 expression shows unfavorable associations in LUSC, ACC, MESO, STAD, LGG and COAD. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify LUSC as the clearest survival context for CCN1 RNA expression.
This table summarizes CCN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in BLCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CCN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCN1 shows lower tumor expression in BLCA, KICH, THCA, KIRP, LIHC and LUSC. The BLCA box plot shows higher CCN1 RNA expression in normal versus tumor tissue (log2 FC = −3.252, t-test p < 0.001).
This table shows molecular features associated with CCN1 in patient tissues and cancer cell lines. In patient samples, CCN1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BONE.
